Kornimate/medical-research-clean huggingface dataset:
evaluation of plasmatic levels of busulfan in patients undergoing hematopoietic stem cell transplantation

Conditions: Acute Leukemia; Chronic Leukemia; Lymphoproliferative Disease; Myeloproliferative Disease; Immunodeficiency

Summary: the purpose of this prospective study is evaluate the best dose of busulfan for each patient undergoing haematopoietic stem cell transplantation

* busulfan is an alkylating antineoplastic agent used commonly during the conditioning regimen in patients undergoing haematopoietic stem cell transplantation (hsct). due to the fact that this drug has a variable metabolism in different individuals, the investigators performed the plasmatic dosage of chemotherapy before starting the conditioning regimen (test dose) as a way to predict the best dose to them during the conditioning. busulfan toxicities depends on the "area under curve" and concentration steady state (css). * the investigators randomized in groups according to the route of drug administration: per oral and intravenously. dose test will be performed before conditioning and othe pharmacokinetics (pk) study will be made in the first day of conditioning. the test dose of p.o busulfan will be 1 mg/kg/dose and 32 mg/m2 for i.v busulfan. the target dose of busulfan during the conditioning will depends on the pk obtained during the test dose. in the first day of regimen, other samples will be analysed and the new auc will be adjusted. we will have a control group who have never performed monitoring before (retrospective group) * test dose for oral busulfan will be performed with peripheral blood samples at the time: 0h (before taking busulfan), 30', 1h, 1,5h, 2h, 3h, 4h, 5h and 6h. in the first day of conditioning other samples will be collected again in the same moments. * test dose for i.v busulfan will be performed on time 0h, 30', 45', 1h, 2h, 3h, 4h, 5h, 6h and 8h after receiving i.v busulfan. if the patients will receive i.v busulfan during conditioning, the blood samples should be collected on time 0h, 30', 1h, 2h, 3h, 4h, 5h, 6h, 7h and 8h after taking busulfan. the blood samples will be centrifuged (4º c/ 3200 rpm/10 minutes) and analysed. * patients will be monitored with pharmacokinetic's drug and clinical outcomes. the investigators will evaluate acute and chronic toxicities after stem cell transplantation.

Eligibility criteria:
inclusion criteria: * diagnosis of hematologic or non-hematologic pathology using as part of the conditioning regimen busulfan; * men, women and children regardless of age; * performance status\> 80 or ecog \<2; * total bilirubin \<2 mg / dl and transaminases \<3 times the upper limit of normal; * creatinine \<1.5 mg / dl; * lvef\> 50% by echocardiogram or muga at rest; * pulmonary function test with fev1\> 70%; * consent form signed before the start of any specific procedure. exclusion criteria: * presence of infectious process in uncontrolled activity; * presence of psychiatric disorder; * pregnancy;

Keywords: busulfan plasmatic dosage stem cell transplantation
study of household purchasing patterns, eating and recreation

Conditions: Dietary Habits; Adiposity; Blood Pressure

Summary: this project examines behavioral and household characteristics associated with food purchasing patterns.


Eligibility criteria:
inclusion criteria: 1. adult individual who reports making at least 75% of household food purchases 2. resides in city of chicago, illinois or surrounding suburbs exclusion criteria: 1. inability to provide informed consent in english 2. living in transitional housing or on a college campus 3. lack of a cellular or land line phone 4. gang presence or illegal activity in the immediate vicinity of the home, or other factors jeopardizing researcher safety during home visits (e.g., extreme unsanitary conditions) 5. having a household member, including the primary shopper, with a medical condition or food allergy that substantially influences household food choices (e.g., phenylketonuria, celiac disease)
genetic epidemiology of venous thromboembolism

Conditions: Cardiovascular Diseases; Venous Thromboembolism

Summary: to determine the genetic epidemiology, including genetic and environmental interactions of the multifactorial disease, venous thromboembolism (vte).

background: venous thromboembolism is a major national health problem, with at least 201,000 first lifetime cases per year in the united states. over 50,000 of these patients die within seven days, and for 20 percent, death is rapid, with insufficient time for medical intervention. recurrent vte is frequent and also associated with death as well as chronic impairment due to the venous stasis syndrome. thus, identification of high-risk patients for targeted vte prophylaxis or treatment is necessary to improve survival and prevent impairment. while clinical risk factors can identify a population at risk, such risk factors have low predictive value for the individual patient. the high prevalence of the factor v r506q (leiden) and prothrombin 20210g --\> a mutations among vte patients suggests the hypothesis that additional genetic abnormalities of coagulation (thrombophilia) are associated with a substantial proportion of vte cases. design narrative: the study had a case-control design. using stored dna samples, the investigators screened for mutations within the candidate genes for factor v r506q (leiden) and prothrombin 20210g --\> a using either dideoxy, bi-directional dideoxy, or restriction endonuclease fingerprinting, and performing population-based case-control and cohort studies using a previously identified 30-year vte inception cohort. the specific aims were: 1) to screen genomic dna from patients with vte for mutations within (candidate) genes encoding for prothrombin, thrombomodulin, tissue factor pathway inhibitor, tissue factor, factor vii, and factor x, and to determine if the mutation predicted a change in either protein expression or structure; 2) in population-based case-control studies, a) to test the hypothesis that such a mutation was associated with vte, estimate the strength of the association, and determine the independence of the association after controlling for other environmental risk factors and coagulation abnormalities, including interactions, and b) to test the hypothesis that a mutation was associated with death and autopsy; 3) to estimate the attributable risk for vte associated with each significant mutation, both individually and for all independently significant mutations collectively while controlling for other environmental risk factors and coagulation abnormalities; and 4) in a population-based retrospective cohort study, to estimate the time-to-vte recurrence and to test the hypothesis that each significant mutation was an independent predictor of vte recurrence after controlling for other environmental predictors and coagulation abnormalities, including interactions.

Eligibility criteria:
no eligibility criteria
ministop plus program for pre-school children with overweight and obesity

Conditions: Obesity, Childhood

Summary: the mobile-based intervention intended to stop obesity in preschoolers (ministop) program has been developed to be a comprehensive digital support program for all children irrespective of weight status. however, a one size fits all approach may not be sufficient as some families may require extra support through in-person activities to achieve the required lifestyle behaviour change in order to attain and maintain a healthy weight. therefore, the aims of this pilot randomized controlled trial are to evaluate the efficacy and feasibility of the ministop plus program in pre-school children with overweight and obesity on: (i) children's bmi z-scores; (ii) intake of fruit and vegetables, sweet and savoury snacks, and sweet drinks; (iii) time spent in different physical activity intensities; (iv) screen time; and (v) parental self-efficacy.


Eligibility criteria:
inclusion criteria: * 2 to 5 year old children with overweight and obesity residing in the municipality of kungsbacka. exclusion criteria: * if a child has a disease or disorder that affects body size or feeding. * children who have a parent suffering from a serious physical or psychological disease making the study too demanding for the family. * children from families who will not be able to understand the app content, i.e., those who do not speak swedish, english, arabic, or somali
focal therapy for localized prostate cancer

Conditions: Prostate Cancer

Summary: this prospective registry and longitudinal study that is designed to carefully measure details of prostate cancer patients' outcomes with focal therapy. the goal of which is to improve patient care.

this observational study will serve to collect data from medical record and review questionnaires before and after focal ablation of prostate tissue. all enrolled subjects will have already undergone or scheduled to receive the focal therapy as part of their prostate cancer treatment.

Eligibility criteria:
inclusion criteria: * subject has elected or already undergone focal therapy as their standard of care treatment method and declined alternative treatment (active surveillance, radical prostatectomy, and radiation therapy) * psa ≤ 20 * ability to complete informed consent form exclusion criteria: * contraindication to follow-up multi parametric mri or prostate biopsy * unable to tolerate general or regional anesthesia

Keywords: focal therapy high intensity frequency ultrasound transurethral ultrasound ablation cryoablation irreversible electroporation
community kangaroo mother care for improving child survival and brain development in low birth weight newborns

Conditions: Low Birth Weight

Summary: while newborn and child survival remains a priority, optimal development of survivors is receiving increasing attention. interventions that impact both survival and development should be prioritized for action. kangaroo mother care (kmc) improves survival, and potentially neurodevelopment, in preterm and low birth weight infants in hospital settings but its coverage remains low. innovation is required to allow the community-based delivery of kmc by front-line workers. this could greatly accelerate scale up and sustainability of this intervention in low resource settings. the proposed randomized trial is planned in a setting where 40% of births take place at home. early discharge (as early as within 12 hours of birth) is common for facility births, often at the request of families for social and cultural reasons. many of the hospitals do not have incubators for the care of very small babies.

low birth weight (lbw) infants will be identified through surveillance. eligible infants will be randomized into the intervention and control groups. mother in the intervention group will be supported by a anm-like study workers assisted by asha-like study workers to provide kangaroo mother care (kmc) to their babies at home. breastfeeding support will also be provided to these mothers by anm-like study workers. essential newborn care will be delivered through government workers in both groups. survival will be measured in all enrolled infants through contacts at 1, 3, 6 and 12 months of age. information will also be ascertained on initiation of breastfeeding, exclusive breastfeeding rates, incidence of infection in the neonatal and in the 1-5 months period. development outcomes (maternal depression, maternal sense of competence, mother-infant bonding, mother-infant interaction, newborn behaviour, infant temperament, brain development) will be measured at enrolment, 6weeks, 6 and 12 months of age. growth will be measured at enrolment and at 1, 3, 6 and 12 months.

Eligibility criteria:
inclusion criteria - mothers and low birth weight ≥1500gms to ≤2250gms exclusion criteria * birth weight \<1500gms * unable to feed on offering feeds, confirmed by study team * infant has breathing problems or less active * mother does not intend to stay in study area for the next 12 months

Keywords: kangaroo mother care in the community
effect of a new bi-specific antibody towards dendritic cells on inflammation in rheumatoid arthritis

Conditions: Rheumatoid Arthritis; Gout; Osteoarthritis

Summary: first, this study will evaluate, in vitro, the cellular composition of the synovial fluid from patient with rheumatoid arthritis, gout or osteoarthritis. then samples will be test with a new format of bispecific antibody targeting dendritic cells. the production of il-10 will be the principal criteria of judgment. production of others cytokines like il-1b, il-6, il-12 and ifn will be checked as well.

rheumatoid arthritis (ra) is one of the most common autoimmune disease in adult. it exists several drugs but none target dendritic cells even if it seems they play a major role in the physiopathology. one of the unit of research of tours recently develop a new format of bispecific antibody which target dendritic cells. the first results in pbmc (unpublished yet) show an increase of the production of il-10 in this study, we are going to first evaluate the cellular composition of synovial fluid from patients with ra and patients with gout (for the comparison, because the inflammatory mechanisms are different) and with osteoarthritis (comparison with a non inflammatory disease) then, we will use this new antibody and evaluate the response by dosing il-10, il-6, il-12, il1b and ifny the aim is to verify in vitro if, with this new drug, it is possible to reverse the inflammation and induce a tolerance.

Eligibility criteria:
inclusion criteria: * male or female over 18 years old * proven and possible ra or gout or osteoarthritis * arthritis accessible to a puncture * necessary puncture for diagnosis or therapeutic exclusion criteria: * microcrystalline rheumatism other than gout * known spa * septic arthritis * biomedicament treatment * patient having objected to the processing of his data

Keywords: rheumatoid arthritis dendritics cells
artificial intelligence and smart wearable technologies for early detection of acute heart failure

Conditions: Heart Failure，Congestive

Summary: heart failure is the major pandemic of the 21st century. the number of patients and of heart failure-related deaths is progressively increasing. this means a devastating economic and health organization burden. in fact, chronic heart failure patients are at high risk of death, and the course of the disease is often insidious and uncertain with a progressive deterioration requiring the need for repeated and successive hospitalizations with an ominous prognosis: with each admission for acute heart failure there is a short-term improvement, a phase characterized by a degree of stability, and then a worsening phase follows until a new need for a new hospitalization. moreover, with each subsequent hospitalization, myocardial function progressively declines, gradually worsening the patient's quality of life until the fatal event. for these reasons, one of the major unmet needs is the identification of patients with a negative trajectory of heart failure. accordingly, early identification of heart failure worsening is mandatory to improve patient condition and reduce heart failure costs, which are mainly associated with hospitalizations. our main goal through this project is to create clinical tool for detection of early signs of chronic heart failure (chf) worsening that will allow timely therapeutic intervention. this timely manner intervention can lead to a much better outcome for the patient, possibly reducing the need for hospitalization or lower the number of hospitalization days. the aim of this project is to develop clinical decision tool based on artificial intelligence (ai) algorithms to early detect the signs of exacerbation of chronic heart failure and predict the risk of its progression, by integrating high quality medical data obtained through a wearable device (l.i.f.e. italia srl's "wearable clinic" - a vest with accessories, which is a trl 9 medical grade sensorized garment, already available on the market). specifically, the focus will be on the early detection of chf worsening in patients who have already been diagnosed with chf.


Eligibility criteria:
inclusion criteria: * presence of symptoms and/or signs of hf * left ventricular ejection fraction (lvef) ≤40%. lvef values will be obtained by determining the reduced lv systolic function, by transthoracic echocardiographic assessment as recommended by european association of cardiovascular imaging (eacvi) and american society of echocardiography position paper. * nyha functional classes ii-iii). exclusion criteria: * nyha functional class iv, * candidates for left-ventricular assist device (lvad) or heart transplant, as per latest definition of heart failure association of the esc. * recent acute coronary syndrome within 1-year prior to the date of potential enrollment, * indirect echocardiographic evidence of significantly elevated pulmonary pressures * clinically relevant pulmonary hypertension * non-adherence to optimal medical treatment for chf
prevalence of skin sensitization and dermatitis among epoxy-exposed workers in the wind turbine industry.

Conditions: Dermatitis

Summary: the goal of this observational study it to learn about the prevalence of skin sensitization and dermatitis among epoxy-exposed workers in the wind turbine industry. the main question it aims to answer is: - what is the prevalence of skin sensitization and dermatitis among workers in the wind turbine industry who are exposed to epoxy? participants will be asked to perform patch test, which is considered the gold standard test for identifying the cause of occupational contact allergic dermatitis. researchers will compare the results of the epoxy-exposed group with those of a control group comprising non-exposed workers from the same industry. this analysis will help determine if there is a higher prevalence of skin sensitization among workers exposed to epoxy.

epoxy resin systems are widely used materials in various industries due to their high mechanical, chemical, and thermal resistance. these systems are commonly employed as protective coatings, adhesives, and paints, as well as in the manufacturing of composites in the plastics industry. epoxy components are well-known sensitizers of the skin. a high prevalence of skin sensitization and dermatitis have been reported among workers exposed to epoxy components. it is recommended to use comprehensive protective equipment when handling epoxy components. in the wind turbine industry, tasks involving epoxy handling, such as lamination and filling procedures, are frequently performed. recent study have shown a sensitization prevalence of 8.9% among workers performing these tasks, while a previous study reported a high sensitization rate of 10.5% to epoxy resins. despite efforts to find alternatives to epoxy resin systems and improve protective measures, the use of epoxy has increased, and some countries have implemented more stringent regulations, such as denmark. in portugal, there are currently no specific regulations regarding epoxy handling, and no certification is required for working with epoxy. siemens gamesa renewable energy, in portugal, faces many skin problems among production workers, however numbers are unknown. therefore, the main purpose of the study is to evaluate the prevalence of skin sensitization and dermatitis among epoxy-exposed workers in the wind turbine industry.

Eligibility criteria:
inclusion criteria: * workers from the wind turbine industry exclusion criteria: * pregnant females * workers previously diagnosed with epoxy resin sensitization
the indorse study: inhibition of dipeptidyl peptidase iv: outcomes on renal sodium excretion

Conditions: Type 2 Diabetes

Summary: background: dedicated renal hemodynamic and renal function studies are lacking for dpp-4 inhibitors in patients with type 2 diabetes; accordingly little is known regarding the mechanisms mediating the renal effects of dpp-4 inhibitors in humans. objectives: to evaluate the effect of dpp-4 inhibition acutely (single dose) and following short-term therapy (28 days) on renal sodium handling and renal hemodynamics and function in patients with type 2 diabetes and systolic hypertension. design: double-blind, randomized, placebo-controlled trial, phase iv. patient population: 32 patients with type 2 diabetes, hba1c (6.5%-9%), with systolic blood pressure ranging from 120-160 mmhg. intervention: subjects will be randomized (1:1) to either sitagliptin (100 mg daily) or to placebo (1 tablet daily) for 28 days. endpoints: fractional excretion of sodium, renal function, and renal hemodynamics.

background: dpp-4 inhibition improves glycemic control, modestly reduces blood pressure and may also reduce albuminuria in patients with type 2 diabetes; effects which occur without significantly modifying heart rate or body weight. while preclinical studies have demonstrated that dpp-4 inhibition acutely increases urinary sodium excretion in addition to other favorable renal effects (anti-inflammatory, anti-proteinuric), few studies have examined the renal effects of dpp-4 inhibition either acutely or following short-term therapy in humans with type 2 diabetes. considering the world-wide prevalence of type 2 diabetes and the increasing use of dpp-4 inhibitors amongst patients, it is important to ascertain potential non-glycemic effects of dpp-4 inhibitors including those within the kidney. study objectives: to determine effect(s) of dpp-4 inhibition on tubular sodium handling, renal hemodynamics, and renal function. study design: double-blind, randomized, placebo-controlled trial, phase iv. study patients: 32 patients with type 2 diabetes and systolic hypertension (sbp 120-160 mmhg). endpoints: fractional excretion of sodium, renal function (measured gfr), renal hemodynamics (effective renal plasma flow, filtration fraction, renal blood flow, renal vascular resistance), systemic hemodynamics (non-invasive cardiac monitoring), plasma neurohormones, urinary vasoactive mediators, markers of free radical stress.

Eligibility criteria:
inclusion criteria: * individuals of 18-70 years of age, * with type 2 diabetes, * with an hba1c (6.5%-9%), * and with a systolic blood pressure (120-160 mmhg). exclusion criteria: * individuals with: 1. type 1 diabetes, 2. egfr \<50ml/min/1.73m, 3. pregnancy or breast feeding, 4. significant cardiac, pulmonary or liver disease, 5. prior history of pancreatitis, medullary thyroid cancer, multiple endocrine neoplasia syndromes, 6. sbp \>161 mmhg, 7) dbp \>100 mmhg, 7. alcohol or substance abuse, 8. states of secondary hypertension.

Keywords: type 2 diabetes, dpp-4 inhibitors, renal sodium excretion